FIELD: pharmacology.
SUBSTANCE: group of inventions concerns a peptide containing the glycine-arginine-glycine-cysteic acid-threonine-proline sequence, which inhibits cell adhesion to RGD binding sites. A composition, and a method for vitreoretinal disease treatment, and a method for stimulation of vitreolysis, dilation of the vitreous or vitreoretinal detachment are also described.
EFFECT: group of inventions provides treatment of retinal diseases or simplified removal of the vitreous body during vitrectomy.
10 cl, 6 ex, 5 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
| COMPOSITIONS AND METHODS FOR ANGIOGENESIS SUPPRESSION | 2010 |
|
RU2786127C2 |
| TECHNIQUES AND COMPOSITIONS USED TO INHIBIT αβ-CAUSED ANGIOGENESIS | 1997 |
|
RU2195312C2 |
| METHODS AND COMPOSITION USEFUL FOR ANGIOGENESIS INHIBITION | 1995 |
|
RU2162712C2 |
| RGD-CONTAINING PEPTIDOMIMETICS AND THEIR APPLICATION | 2009 |
|
RU2519736C2 |
| PEPTIDE COMPOUNDS | 2005 |
|
RU2393167C2 |
| PEPTIDE-BASED COMPOUNDS FOR DIRECTED TRANSPORT TO INTEGRIN RECEPTORS | 2002 |
|
RU2303042C2 |
| INHIBITORS OF INTEGRIN FOR TREATING OCULAR DISEASES | 2002 |
|
RU2311177C2 |
| METHOD FOR THE TREATMENT OF PROLIFERATIVE PROCESSES OF THE POSTERIOR SEGMENT OF THE EYE | 2018 |
|
RU2684927C1 |
| METHODS AND COMPOSITIONS USED FOR INHIBITING ANGIOGENESIS | 1997 |
|
RU2194528C2 |
